Search results
Hollings Renton Sells 1,950 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock
ETF DAILY NEWS· 7 days agoAnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director Hollings Renton sold 1,950 shares of the business’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average ...
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks via Yahoo Finance· 4 days agoARQT is a late-stage biopharmaceutical company. ARQT is focused on developing and commercializing ...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 4 days agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
Harbor Investment Advisory LLC Increases Stake in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 8 hours agoHarbor Investment Advisory LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 0.7% in the first quarter, according to its most recent filing with the Securities and ...
Austin Private Wealth LLC Increases Stock Holdings in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 6 hours agoAustin Private Wealth LLC raised its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 6.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission ...
Psoriatic Arthritis Drugs Comparably Improve Joint Outcomes
Medscape· 7 days agoReal-world study data suggest there is little difference among five drug classes commonly used to...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 6 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 3 days agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks· 5 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 7 days agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...